Acceleron Pharma
Biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics.
Launch date
Employees
Market cap
-
Enterprise valuation
€10.5b (Public information from Sep 2021)
Share price
$178.75
Cambridge Massachusetts (HQ)
Financials
Estimates*
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 13.0m | 14.0m | 74.0m | 92.0m | 135m | 201m |
| % growth | - | - | 8 % | 429 % | 24 % | 47 % | 49 % |
| EBITDA | - | (107m) | (121m) | (133m) | (163m) | (250m) | (234m) |
| % EBITDA margin | - | (823 %) | (864 %) | (180 %) | (177 %) | (185 %) | (116 %) |
| Profit | - | (108m) | (119m) | (125m) | (166m) | (241m) | (203m) |
| % profit margin | - | (831 %) | (850 %) | (169 %) | (180 %) | (179 %) | (101 %) |
| EV / revenue | - | 126.4x | 122.9x | 32.2x | 74.5x | - | 54.3x |
| EV / EBITDA | - | -15.4x | -14.2x | -17.9x | -42.1x | - | -46.6x |
| R&D budget | 58.3m | 70.4m | 86.9m | 138m | - | - | - |
| R&D % of revenue | - | 542 % | 621 % | 186 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $9.0m | Convertible | |
| N/A | $9.1m | Series A | |
$8.0m | Debt | ||
$30.0m | Series B | ||
$31.0m | Series C | ||
$11.0m | Late VC | ||
$10.3m | Early VC | ||
| N/A | $1.5m | Grant | |
$30.0m | Series F | ||
| N/A | $83.7m Valuation: $385m | IPO | |
* | N/A | $129m | Post IPO Equity |
* | N/A | $150m | Post IPO Equity |
| N/A | $216m | Post IPO Equity | |
* | N/A | $265m | Post IPO Equity |
* | N/A | $450m | Post IPO Equity |
$11.5b Valuation: $11.5b 125.0x EV/LTM Revenues -70.5x EV/LTM EBITDA | Acquisition | ||
| Total Funding | €120m | ||
Related Content
Recent News about Acceleron Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.